NASDAQ:UBX - Unity Biotechnology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.24 -0.01 (-0.09 %)
(As of 02/18/2019 01:55 PM ET)
Previous Close$11.25
Today's Range$11.07 - $11.70
52-Week Range$10.33 - $24.56
Volume111,389 shs
Average Volume181,544 shs
Market Capitalization$475.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UBX
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$475.71 million
OptionableNot Optionable

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Unity Biotechnology.

What price target have analysts set for UBX?

4 brokers have issued 1 year target prices for Unity Biotechnology's shares. Their predictions range from $17.00 to $33.00. On average, they anticipate Unity Biotechnology's stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 135.8% from the stock's current price. View Analyst Price Targets for Unity Biotechnology.

What is the consensus analysts' recommendation for Unity Biotechnology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unity Biotechnology.

Has Unity Biotechnology been receiving favorable news coverage?

News coverage about UBX stock has been trending somewhat positive recently, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Unity Biotechnology earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of Unity Biotechnology's key competitors?

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the folowing people:
  • Mr. Keith R. Leonard Jr., Exec. Chairman & CEO (Age 57)
  • Dr. Nathaniel E. David, Co-Founder, Pres & Director (Age 51)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi Ph.D., Founder
  • Mr. Daohong Zhou M.D., Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.37%), Northern Trust Corp (0.54%), Geode Capital Management LLC (0.34%), Bank of New York Mellon Corp (0.14%), Rhumbline Advisers (0.07%) and Cerity Partners LLC (0.05%).

Which institutional investors are buying Unity Biotechnology stock?

UBX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Geode Capital Management LLC, Bank of New York Mellon Corp, Rhumbline Advisers, Cerity Partners LLC, Virtus ETF Advisers LLC and Bank of America Corp DE.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $11.24.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $475.71 million.


MarketBeat Community Rating for Unity Biotechnology (NASDAQ UBX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  82
MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote "Outperform" if you believe UBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel